It starts with a regimen that some patients prefer
In SOLAR, every-2-month CABENUVA was preferred by 9 out of 10 survey respondents vs daily oral therapy with BIKTARVY1,2

At Month 12 analysis or study withdrawal (secondary endpoint), all CABENUVA-treated patients in SOLAR (mITT-E; n=447) were asked to respond to a question about which regimen they preferred. 22 patients did not respond. Of the 425 survey respondents2:

90 percent icon 90 percent icon

90% reported a preference for CABENUVA1,2

SOLAR study showed that some patients prefer an every-2-month injectable vs BIKTARVY

  • Patients were asked to compare their experience using CABENUVA versus BIKTARVY; to select the treatment they preferred; and then select from a list of provided statements to support their preference
  • 5% (n=21/425) preferred BIKTARVY and 5% (n=22/425) had no preference

These results are descriptive in nature and should not be used to infer clinical significance.

  • SOLAR Study Design

    SOLAR is the first head-to-head switch study comparing every-2-month CABENUVA with continuing daily oral BIKTARVY1

    A large, phase 3b, open-label, noninferiority study of virologically suppressed* adults (≥18 years) with HIV-11

    SOLAR study design screening graphic
    SOLAR study design efficacy endpoints graphic
    • Efficacy analyses, baseline questionnaire, and preference calculation were based on the mITT-E (n=670) population. After consultation with a blinded external expert, 11 participants at a single study site were excluded from the ITT-E population due to critical findings related to significant and persistent noncompliance to protocol requirements2
    • Safety analyses were based on ITT-E (N=681) population1,2
    SOLAR study design efficacy endpoints graphic
    1. Suppression defined as plasma HIV-1 RNA <50 copies/mL. A single prior INSTI-based regimen was allowed for reasons other than treatment failure (HIV-1 RNA ≥400 copies/mL).1
    2. Patients randomized to CABENUVA were given the option of 1-month oral lead-in (OLI) or to start long-acting IM CABENUVA directly (SWI). OLI regimen consisted of 30-mg cabotegravir and 25-mg rilpivirine once daily given for 1 month; on last day of the OLI period, patients received 2 sets of initiation CABENUVA injections 1 month apart followed by every-2-month injections thereafter.1-3
Female with black hair in a grey top next to data bars

Identifying patients for
CABENUVA in your practice

Male with a blue hoody Male with a blue hoody

Patient Ambassador - Steve

I was always concerned that somebody would find my pills and discover that I was HIV positive.

See Steve’s HIV treatment story

HBV=hepatitis B virus; IM=intramuscular; INSTI=integrase strand transfer inhibitor; IQR=interquartile range; ITT-E=intent-to-treat exposed; M=month; mITT-E=modified intent-to-treat exposed; SWI=starting with injections.


  1. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):E566-E577.
  2. Data on file. ViiV Healthcare group of companies. Durham, NC.
  3. SOLAR Study. Available at: Accessed February 16, 2023.